Post hoc analysis finds high-dose Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) further reduces asthma exacerbations
A new analysis presented at conference showed a high-dose (150/50/160μg) cut the annualised rate of moderate-or-severe asthma exacerbations by 21% and severe exacerbations by 31% compared with medium-dose (150/50/80μg) over 52 weeks.
Source:
PharmaTimes